←
NIOME12,826 posts
NIOME avatar

NIOME

@NiomeAI

NIOME SN55 - Synthetic genomes for drug discovery. A Bittensor Subnet for programmable biology. From the team behind Genomes.io.

◷ Joined October 2016▧ 2,211 Photos and videos
Yuma avatar
⟳ NIOME retweeted
Yuma@YumaGroup·5h

Niome (SN55) with an AMA this Friday on their updated roadmap's central vision: Make every genetic disease treatable. $TAO

Lots of things happening at NIOME HQ! 🧬 Join us this Friday for our AMA discussing our deeper focus, new Subnet revenues & where we are with the migration. Lots of work to be done! Hope you can make it:) 💪 x.com/i/spaces/1evOrWbKMjpYg…

Subnet Summer avatar
⟳ NIOME retweeted
Subnet Summer@SubnetSummerTAO·13h

NIOME (SN55) is expanding beyond genomics 🧬 Two new capabilities coming to the subnet: • Design: AI models propose potential treatments for genetic diseases • Evaluate: models score how promising each candidate is Why it matters: • Moves SN55 from the genomics market into drug development • Rare disease therapeutics is a $220B+ market this year • AI drug design is attracting serious capital (Isomorphic Labs reportedly raising $5B) genomes.io is also preparing a major equity round to fund what comes next.

What comes next for NIOME (SN55)? Our co-founder and CEO Aldo de Pape explains how NIOME is moving from understanding the genome to acting on it, with one goal at the centre of everything: 𝗺𝗮𝗸𝗲 𝗲𝘃𝗲𝗿𝘆 𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝘁𝗿𝗲𝗮𝘁𝗮𝗯𝗹𝗲. For Subnet 55, this is a major expansion. Alongside generating and analysing genetic data, the network is set to take on two new capabilities: • Design, where AI models propose potential treatments for genetic diseases • Evaluate, where models score how promising each candidate is That moves NIOME beyond the genomics market into the market for developing new medicines, where rare disease therapeutics alone are worth over $220 billion this year. Serious capital is flowing into AI drug design right now, and Isomorphic Labs, the DeepMind spinout, is reportedly in talks to raise $5 billion. To fund what comes next, genomes.io is preparing a major equity investment round, with encouraging conversations already underway with investors and partners. More is coming in the weeks ahead, as NIOME takes its next step toward making every genetic disease treatable.

1:51
Alchemist - τ avatar
⟳ NIOME retweeted
Alchemist - τ@SubnetSummerT·13h

The jump from understanding the genome to acting on it is the interesting part here. Design + Evaluate on SN55 means Bittensor competing in the AI drug design space. Rare disease therapeutics alone is a $220B+ market. Keen to see what Aldo and the team share in the coming weeks.

What comes next for NIOME (SN55)? Our co-founder and CEO Aldo de Pape explains how NIOME is moving from understanding the genome to acting on it, with one goal at the centre of everything: 𝗺𝗮𝗸𝗲 𝗲𝘃𝗲𝗿𝘆 𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝘁𝗿𝗲𝗮𝘁𝗮𝗯𝗹𝗲. For Subnet 55, this is a major expansion. Alongside generating and analysing genetic data, the network is set to take on two new capabilities: • Design, where AI models propose potential treatments for genetic diseases • Evaluate, where models score how promising each candidate is That moves NIOME beyond the genomics market into the market for developing new medicines, where rare disease therapeutics alone are worth over $220 billion this year. Serious capital is flowing into AI drug design right now, and Isomorphic Labs, the DeepMind spinout, is reportedly in talks to raise $5 billion. To fund what comes next, genomes.io is preparing a major equity investment round, with encouraging conversations already underway with investors and partners. More is coming in the weeks ahead, as NIOME takes its next step toward making every genetic disease treatable.

1:51
NIOME avatar
NIOME@NiomeAI·13h

What comes next for NIOME (SN55)? Our co-founder and CEO Aldo de Pape explains how NIOME is moving from understanding the genome to acting on it, with one goal at the centre of everything: 𝗺𝗮𝗸𝗲 𝗲𝘃𝗲𝗿𝘆 𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝘁𝗿𝗲𝗮𝘁𝗮𝗯𝗹𝗲. For Subnet 55, this is a major expansion. Alongside generating and analysing genetic data, the network is set to take on two new capabilities: • Design, where AI models propose potential treatments for genetic diseases • Evaluate, where models score how promising each candidate is That moves NIOME beyond the genomics market into the market for developing new medicines, where rare disease therapeutics alone are worth over $220 billion this year. Serious capital is flowing into AI drug design right now, and Isomorphic Labs, the DeepMind spinout, is reportedly in talks to raise $5 billion. To fund what comes next, genomes.io is preparing a major equity investment round, with encouraging conversations already underway with investors and partners. More is coming in the weeks ahead, as NIOME takes its next step toward making every genetic disease treatable.

1:51
Subnet Summer avatar
⟳ NIOME retweeted
Subnet Summer@SubnetSummerTAO·Nov 17

We’re excited to officially introduce Subnet Summer Marketing. We've seen many projects and subnets on Bittensor struggle to expand their reach and build a stronger social media presence. We've worked with about 8 projects over the last few months and are now ready to apply our experience and strategies to help more subnets grow. To all subnets looking to improve their visibility, explore our services here: marketing.subnetsummer.com

Subnet Summer @SubnetSummerTAO Nov 17 Article Introducing Subnet Summer Marketing There’s a huge gap in marketing across Bittensor. From the last few months of working across the ecosystem, we’ve seen many subnets struggle with marketing, branding, and properly promoting what

NIOME avatar
NIOME@NiomeAI·Nov 13

It is easy to see NIOME as a token on a subnet. Underneath it is a company already working with real clients, backed by names most projects never get near. genomes.io, the team behind NIOME, supplies synthetic genomic data to a live client pipeline. That pipeline reaches a clinical partner, a nutrition-genetics group, and a partnership with the Scottish government, with more going out as the network scales. These are real institutions putting the data to work in live research, from drug-absorption studies to population-scale genetics. The names already associated with NIOME read like a serious science and tech roster: MIT and the University of Aberdeen on the research side, AWS and AMD on the infrastructure, Deloitte and others around it. That credibility is already in the room. You rarely see both at once, customers using the output and institutions this serious behind the work, and almost never this early. Most tokens spend years chasing one of them and never land the other. That is what the migration moves you into: a network already doing the work, already in demand, with the names to show for it.

Post attachment
NIOME avatar
NIOME@NiomeAI·Nov 12

A while back we announced 10 million synthetic CRISPR experiments, complete on Subnet 55. Here is what was behind that number. CRISPR is how modern medicine edits genes, including the edits that could one day treat sickle cell at its root. But editing a genome is not a clean cut. Before you can trust an edit, you have to predict three things: • Whether it lands where you intended. • Whether it also cuts somewhere it should not. • How the cell repairs the break once it is made. Get any of them wrong and the edit fails, or worse. Predicting those outcomes from raw sequence is one of the hardest problems in the field. That is exactly what the challenge took on. The network generated 10 million synthetic editing experiments, each carrying a known outcome, across a huge range of edit sites and genomic contexts. Miners competed to predict the results, and because every answer was known in advance, every prediction could be scored exactly. The result is a benchmark: 10 million scored examples of CRISPR edits and their outcomes, the kind of large, labeled dataset that gene-editing work depends on and rarely has. This is the proof that the model works. It takes a real, hard problem in genome editing and turns it into something an open network of miners can solve at scale, with the output to show for it. The sickle cell CRISPR challenge is done, and it set the bar for everything the subnet takes on next

Post attachment